2023
Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
Murakami N, Borges T, Win T, Abarzua P, Tasigiorgos S, Kollar B, Barrera V, Ho Sui S, Teague J, Bueno E, Clark R, Lian C, Murphy G, Pomahac B, Riella L. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. American Journal Of Transplantation 2023, 23: 549-558. PMID: 36740193, PMCID: PMC10318113, DOI: 10.1016/j.ajt.2023.01.016.Peer-Reviewed Original ResearchMeSH KeywordsFacial TransplantationGraft RejectionHumansInterleukin-2Pilot ProjectsT-Lymphocytes, RegulatoryConceptsLow-dose IL-2 therapyIL-2 therapySkin allograftsFace transplant recipientsTransplant recipientsIL-2Immune regulationLow-dose interleukin-2 (IL-2) therapyHigher acute rejection ratesLow-dose IL-2Face transplantationAcute rejection ratesCytotoxicity-associated genesDose interleukin-2Greater suppressive functionInterleukin-2 therapyAutoimmune hemolytic anemiaRegulatory T cellsNarrow therapeutic windowLife-changing procedureImmunological monitoringTim-3Peripheral bloodImmune modulationHemolytic anemia
2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionImmune TolerancePrecision MedicineT-Lymphocytes, RegulatoryVascularized Composite AllotransplantationConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotolerancemTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis
Eskandari SK, Allos H, Al Dulaijan B, Melhem G, Sulkaj I, Alhaddad JB, Saad AJ, Deban C, Chu P, Choi JY, Kollar B, Pomahac B, Riella LV, Berger SP, Sanders JSF, Lieberman J, Li L, Azzi JR. mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis. Frontiers In Immunology 2022, 13: 899975. PMID: 35757726, PMCID: PMC9229986, DOI: 10.3389/fimmu.2022.899975.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisGranzymesHumansMechanistic Target of Rapamycin Complex 1MiceReceptors, Antigen, T-CellT-Lymphocytes, RegulatoryConceptsRegulatory T cellsT cellsHuman regulatory T cellsHost THumanized mouse modelPro-apoptotic pathwaysSkin allotransplantationClinical efficacyImmunosuppressive potencyIntracytoplasmic expressionTransplant fieldMouse modelCellular therapyHigh expressionTarget cellsRapamycin complex 1Lysosomal granulesFunctional effectsMechanistic targetPatientsApoptosisC-JunGranzymesDrug targetsS6K